286 related articles for article (PubMed ID: 29241144)
1. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
Soussan C; Andersson M; Kjellgren A
Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
[TBL] [Abstract][Full Text] [Related]
2. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations.
Soussan C; Kjellgren A
Int J Drug Policy; 2016 Jun; 32():77-84. PubMed ID: 27184218
[TBL] [Abstract][Full Text] [Related]
3. Awareness of users and motivational factors for using new psychoactive substances in Belgium.
Simonis S; Canfyn M; Van Dijck A; Van Havere T; Deconinck E; Blanckaert P; Gremeaux L
Harm Reduct J; 2020 Jul; 17(1):52. PubMed ID: 32711526
[TBL] [Abstract][Full Text] [Related]
4. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
Van Hout MC; Hearne E
Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
[TBL] [Abstract][Full Text] [Related]
5. [Prevalence, reasons, and forms of use of legal highs by internet-based survey participants].
Mazurkiewicz MR; Glogowski M; Mrowińska D; Pakulski M; Matyjaszczyk M; Kardas P
Psychiatr Pol; 2013; 47(6):1143-55. PubMed ID: 25007545
[TBL] [Abstract][Full Text] [Related]
6. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
7. Patterns and correlates of new psychoactive substance use in a sample of Australian high school students.
Champion KE; Teesson M; Newton NC
Drug Alcohol Rev; 2016 May; 35(3):338-44. PubMed ID: 26194894
[TBL] [Abstract][Full Text] [Related]
8. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
[TBL] [Abstract][Full Text] [Related]
9. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
Rychert M; Wilkins C; Parker K; Witten K
Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
[TBL] [Abstract][Full Text] [Related]
10. Harm reduction and knowledge exchange-a qualitative analysis of drug-related Internet discussion forums.
Soussan C; Kjellgren A
Harm Reduct J; 2014 Sep; 11():25. PubMed ID: 25200686
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
Sande M
Int J Drug Policy; 2016 Jan; 27():65-73. PubMed ID: 25908121
[TBL] [Abstract][Full Text] [Related]
12. An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS).
Deligianni E; Corkery JM; Schifano F; Lione LA
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28485125
[TBL] [Abstract][Full Text] [Related]
13. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
[TBL] [Abstract][Full Text] [Related]
14. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
Palamar JJ; Martins SS; Su MK; Ompad DC
Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
[TBL] [Abstract][Full Text] [Related]
15. 'What if you live on top of a bakery and you like cakes?'-Drug use and harm trajectories before, during and after the emergence of Silk Road.
Barratt MJ; Lenton S; Maddox A; Allen M
Int J Drug Policy; 2016 Sep; 35():50-7. PubMed ID: 27157539
[TBL] [Abstract][Full Text] [Related]
16. No prescription? No problem: A qualitative study investigating self-medication with novel psychoactive substances (NPS).
Holborn T; Schifano F; Deluca P
Int J Drug Policy; 2023 Aug; 118():104109. PubMed ID: 37422986
[TBL] [Abstract][Full Text] [Related]
17. Characterizing users of new psychoactive substances using psychometric scales for risk-related behavior.
Vreeker A; van der Burg BG; van Laar M; Brunt TM
Addict Behav; 2017 Jul; 70():72-78. PubMed ID: 28214739
[TBL] [Abstract][Full Text] [Related]
18. "Someone Else's Problem": New Psychoactive Substances in the Online Hungarian Media.
Kassai S; Rácz J; Nagy A; Bíbók T; Galambvári É; Kilián C; Gyarmathy VA
J Psychoactive Drugs; 2017; 49(1):47-51. PubMed ID: 28010181
[TBL] [Abstract][Full Text] [Related]
19. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
[TBL] [Abstract][Full Text] [Related]
20. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
Reuter P; Pardo B
Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
